DermaPrep

Dendritic cell targeting is very important for the efficacy of antigen-specific Immune Therapies (therapeutic vaccines). State of Art dendritic cell-based immunizations target the antigen into cultured dendritic cells. To improve such logistically cumbersome ex vivo approaches we developed DermaPrep the first dendritic cell-targeting administration device. Unlike that ex vivo technology, our Immune Therapy products can be manufactured in sizeable batches and administered topically with DermaPrep. One immunization procedure takes ca. 20 minutes and after three hours the patient removes the patch.

DermaPrep employs a skin preparation method that interrupts the stratum corneum facilitating the epidermal penetration of our nanomedicine Product applied on the skin surface under our specially designed patch. The Langerhans cells, located in the skin under our patch, then look for pathogens and 800,000 of them has the chance to capture our "pathogen-like" nanomedicine and travel to the local lymph nodes. Here Langerhans cells mature to antigen-presenting dendritic cells. These cells secrete cytokines to induce Th1-polarized antigen-specific precursor/memory T cells that further differentiate into circulating effector or killer cells.